glp 1 studies 2025 GLP-1 Drugs: Pulse Survey (U.S.) GLP-1 trends 2025: real-world data,

In January 2025, the FDA approved semaglutide for kidney disease risk reduction in type 2 diabetes patients with CKD, and in late 2025 approved oral Wegovy (semaglutide 25 mg tablet) as the first GLP-1 pill for weight management ( [19] )

Whilst Ozempic does not directly cause yellow urine as a documented side effect, the medication's impact on appetite, fluid intake, and gastrointestinal function can indirectly affect hydration statusthe primary determinant of urine colour

Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease

Its to explore what are they doing and what could be more helpful. Co-authors include Selena Gonzlez-Jordan and Sabrena F